Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to use agnostic genomic evaluation using whole exome sequencing (WES) of a variety of rare hematologic diseases grouped under rare blood diseases and its variants to further elucidate the understanding of the chemistry of these disorders and identify potential actionable mutations that can be targeted with therapies in the context of clinical trials.


Clinical Trial Description

The study team will examine genetic changes, also known as mutations, in the DNA of participants' blood, or if applicable, bone marrow specimen. These types of tests are increasingly used by doctors to improve the accuracy of diagnosis and make decisions during care. This study seeks to understand how many patients will benefit from this testing, and in what ways. The results of this portion of the study are placed in the individual's medical record and are communicated back to each participant. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05028621
Study type Interventional
Source Case Comprehensive Cancer Center
Contact Sudipto Mukherjee, MD, PhD
Phone 1-866-223-8100
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date October 2021
Completion date January 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Active, not recruiting NCT02523040 - A Study of Lenalidomide for Adult Histiocyte Disorders Phase 2